References
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., et al. (1993). The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality of life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365-376.
Ahlberg, K., Ekman, T., & Gaston-Johansson, F. (2004). Levels of fatigue compared to levels of cytokines and hemoglobin during pelvic radiotherapy: A pilot study. Biological Research for Nursing, 5(3), 203-210.
Ahlberg, K., Ekman, T., Gaston-Johansson, F., & Mock, V. (2003). Assessment and management of cancer-related fatigue in adults. Lancet, 362(9384), 640-650.
Andrews, N. C. (2004). Anemia of inflammation: The cytokine-hepcidin link. Journal of Clinical Investigation, 113(9), 1251-1253.
Barnes, E. A., & Bruera, E. (2002). Fatigue in patients with advanced cancer: A review. International Journal of Gynecological Cancer, 12(5), 424-428.
Bataille, R., Barlogie, B., Lu, Z. Y., Rossi, J. F., Lavabre-Bertrand, T., Beck, T., et al. (1995). Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood, 86(2), 685-691.
Bohlius, J., Wilson, J., Seidenfeld, J., Piper, M., Schwarzer, G., Sandercock, J., et al. (2006). Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients. Journal of the National Cancer Institute, 98(10), 708-714.
Bower, J. E., Ganz, P. A., Desmond, K. A., Rowland, J. H., Meyerowitz, B. E., & Belin, T. R. (2000). Fatigue in breast cancer survivors: Occurrence, correlates, and impact on quality of life. Journal of Clinical Oncology, 18(4), 743-753.
Brown, D. J., McMillan, D. C., & Milroy, R. (2005). The correlation between fatigue, physical function, the systemic inflammatory response, and psychological distress in patients with advanced lung cancer. Cancer, 103(2), 377-382.
Clearfield, M. B. (2005). C-reactive protein: A new risk assessment tool for cardiovascular disease. Journal of the American Osteopathic Association, 105(9), 409-416.
Collado-Hidalgo, A., Bower, J. E., Ganz, P. A., Cole, S. W., & Irwin, M. R. (2006). Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clinical Cancer Research, 12(9), 2759-2766.
Dimeo, F., Schmittel, A., Fietz, T., Schwartz, S., Kohler, P., Boning, D., et al. (2004). Physical performance, depression, immune status and fatigue in patients with hematological malignancies after treatment. Annals of Oncology, 15(8), 1237-1242.
Durie, B. G., Kyle, R. A., Belch, A., Bensinger, W., Blade, J., Boccadoro, M., et al. (2003). Myeloma management guidelines: A consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematology Journal, 4(6), 379-398.
Gutstein, H. B. (2001). The biologic basis of fatigue. Cancer, 92(6, Suppl.), 1678-1683.
Hair, J. F., Anderson, R. E., Tatham, R. L., & Black, W. C. (1998). Multivariate data analysis (5th ed.). Upper Saddle River, NJ: Prentice Hall.
Harousseau, J. L., & Moreau, P. (2002). Prognostic factors in myeloma. In J. Mehta & S. Singhal (Eds.), Myeloma (pp. 169-183). London: Martin Dunitz.
Hideshima, T., Bergsagel, P. L., Kuehl, W. M., & Anderson, K. C. (2004). Advances in biology of multiple myeloma: Clinical applications. Blood, 104(3), 607-618.
Holzner, B., Kemmler, G., Greil, R., Kopp, M., Zeimet, A., Raderer, M., et al. (2002). The impact of hemoglobin levels on fatigue and quality of life in cancer patients. Annals of Oncology, 13(6), 965-973.
Illman, J., Corringham, R., Robinson, D., Jr., Davis, H. M., Rossi, J. F., Cella, D., et al. (2005). Are inflammatory cytokines the common link between cancer-associated cachexia and depression? Journal of Supportive Oncology, 3(1), 37-50.
Kurzrock, R. (2001). The role of cytokines in cancer-related fatigue. Cancer, 92(6, Suppl.), 1684-1688.
Kyle, R. A., Gertz, M. A., Witzig, T. E., Lust, J. A., Lacy, M. Q., Dispenzieri, A., et al. (2003). Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clinic Proceedings, 78(1), 21-33.
Lee, B. N., Dantzer, R., Langley, K. E., Bennett, G. J., Dougherty, P. M., Dunn, A. J., et al. (2004). A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation, 11(5), 279-292.
Lind, M., Vernon, C., Cruickshank, D., Wilkinson, P., Littlewood, T., Stuart, N., et al. (2002). The level of haemoglobin in anaemic cancer patients correlates positively with quality of life. British Journal of Cancer, 86(8), 1243-1249.
Ludwig, H., Rai, K., Blade, J., Dammacco, F., Degos, L., Itri, L., et al. (2002). Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: Epoetin treatment recommendations. Hematology Journal, 3(3), 121-130.
Maccio, A., Madeddu, C., Massa, D., Mudu, M. C., Lusso, M. R., Gramignano, G., et al. (2005). Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: Role of inflammation in cancer-related anemia. Blood, 106(1), 362-367.
Mazhar, D., Gillmore, R., & Waxman, J. (2005). COX and cancer. QJM: An International Journal of Medicine, 98(10), 711-718.
Morrow, G. R., Andrews, P. L., Hickok, J. T., Roscoe, J. A., & Matteson, S. (2002). Fatigue associated with cancer and its treatment. Supportive Care in Cancer, 10(5), 389-398.
Morrow, G. R., Shelke, A. R., Roscoe, J. A., Hickok, J. T., & Mustian, K. (2005). Management of cancer-related fatigue. Cancer Investigation, 23(3), 229-239.
Nemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B. K., et al. (2004). IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. Journal of Clinical Investigation, 113(9), 1271-1276.
Olson, K., & Morse, J. (2005). Delineating the concept of fatigue using a pragmatic utility approach. In J. Cutcliff & H. McKenna (Eds.), The essential concepts of nursing (pp. 141-159). Oxford, England: Elsevier Science.
Olson, K., Tom, B., Hewitt, J., Whittingham, J., Buchanan, L., & Ganton, G. (2002). Evolving routines: Preventing fatigue associated with lung and colorectal cancer. Qualitative Health Research, 12(5), 655-670.
Olson, K., Turner, A. R., Courneya, K. S., Field, C., Man, G., Cree, M., et al. (2008). Possible links between behavioral and physiological indices of tiredness, fatigue, and exhaustion in advanced cancer. Supportive Care in Cancer, 16(3), 241-249.
Osoba, D., Aaronson, N., Zee, B., Sprangers, M., & te Velde, A. (1997). Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer. Quality of Life Research, 6(2), 103-108.
Palumbo, A., Bertola, A., Musto, P., Caravita, T., Callea, V., Cangialosi, C., et al. (2004). A prospective randomized trial of oral melphalan, prednisone, thalidomide (MPT) vs oral melphalan, prednisone (MP): An interim analysis. Blood, 104(11), 207.
Prue, G., Rankin, J., Allen, J., Gracey, J., & Cramp, F. (2006). Cancer-related fatigue: A critical appraisal. European Journal of Cancer, 42(7), 846-863.
Ringdal, K., Ringdal, G. I., Kaasa, S., Bjordal, K., Wisloff, F., Sundstrom, S., et al. (1999). Assessing the consistency of psychometric properties of the HRQoL scales within the EORTC QLQ-C30 across populations by means of the Mokken Scaling Model. Quality of Life Research, 8(1-2), 25-43.
Rivera, S., Liu, L., Nemeth, E., Gabayan, V., Sorensen, O. E., & Ganz, T. (2005). Hepcidin excess induces the sequestration of iron and exacerbates tumor-associated anemia. Blood, 105(4), 1797-1802.
Rossi, J. F., Fegueux, N., Lu, Z. Y., Legouffe, E., Exbrayat, C., Bozonnat, M. C., et al. (2005). Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140mg/m2 of melphalan in multiple myeloma: Results of a pilot study including biological aspects. Bone Marrow Transplantation, 36(9), 771-779.
Ryan, J. L., Carroll, J. K., Ryan, E. P., Mustian, K. M., Fiscella, K., & Morrow, G. R. (2007). Mechanisms of cancer-related fatigue. Oncologist, 12(Suppl. 1), 22-34.
Schubert, C., Hong, S., Natarajan, L., Mills, P. J., & Dimsdale, J. E. (2007). The association between fatigue and inflammatory marker levels in cancer patients: A quantitative review. Brain, Behavior, and Immunity, 21(4), 413-427.
Scott, H. R., McMillan, D. C., Forrest, L. M., Brown, D. J., McArdle, C. S., & Milroy, R. (2002). The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. British Journal of Cancer, 87(3), 264-267.
Sharma, S., Nemeth, E., Chen, Y. H., Goodnough, J., Huston, A., Roodman, G. D., et al. (2008). Involvement of hepcidin in the anemia of multiple myeloma. Clinical Cancer Research, 14(11), 3262-3267.
Trikha, M., Corringham, R., Klein, B., & Rossi, J. F. (2003). Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: A review of the rationale and clinical evidence. Clinical Cancer Research, 9(13), 4653-4665.
Turner, R., Anglin, P., Burkes, R., Couture, F., Evans, W., Goss, G., et al. (2001). Epoetin alfa in cancer patients: Evidence-based guidelines. Journal of Pain and Symptom Management, 22(5), 954-965.
van Zaanen, H. C., Lokhorst, H. M., Aarden, L. A., Rensink, H. J., Warnaar, S. O., van der Lelie, J., et al. (1998). Chimaeric anti-interleukin-6 monoclonal antibodies in the treatment of advanced multiple myeloma: A phase I dose-escalating study. British Journal of Haematology, 102(3), 783-790.
Wisloff, F., Gulbrandsen, N., Hjorth, M., Lenhoff, S., & Fayers, P. (2005). Quality of life may be affected more by disease parameters and response to therapy than by haemoglobin changes. European Journal of Haematology, 75(4), 293-298.
Wood, L. J., Nail, L. M., Gilster, A., Winters, K. A., & Elsea, C. R. (2006). Cancer chemotherapy-related symptoms: Evidence to suggest a role for proinflammatory cytokines. Oncology Nursing Forum, 33(3), 535-542.
Wratten, C., Kilmurray, J., Nash, S., Seldon, M., Hamilton, C. S., O'Brien, P. C., et al. (2004). Fatigue during breast radiotherapy and its relationship to biological factors. International Journal of Radiation Oncology, Biology, Physics, 59(1), 160-167.
Yang, J., Wezeman, M., Zhang, X., Lin, P., Wang, M., Qian, J., et al. (2007). Human C-reactive protein binds activating Fcy receptors and protects myeloma tumor cells from apoptosis. Cancer Cell, 12(3), 252-265.
Yellen, S. B., Cella, D. F., Webster, K., Blendowski, C., & Kaplan, E. (1997). Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. Journal of Pain and Symptom Management, 13(2), 63-74.
Yi, Q., Yang, J., Wezeman, M., Zhang, X., Qian, J., Hong, S., et al. (2007). C-reactive protein protects myeloma cells from apoptosis via activating ITAM-containing FcyRII. Haematologica, 92(Suppl. 2), PO-210.